Riitta Lahesmaa’s Post

Congrats to Carol Greider and Kayarash Karimian for publishing this vital work in Science Magazine. Measuring the length of all telomeres in the human genome is a milestone in our understanding of telomere biology and in the potential detection and treatment of telomere-associated aging and health-related matters. Of course, this is only made possible by native Oxford Nanopore Technologies sequencing, which works on any fragment length, has no GC or repeat bias, and preserves all modification/epigenetic information. https://lnkd.in/ddB3awJK

🚀 As we look forward to SynBioBeta 2024, we're reflecting on last year's Main Stage Panel: Revolutionizing Medicine with Synthetic Biology, an awesome discussion where we explored the boundless potential of synthetic biology in revolutionising the future of medicine! 🧬 Moderated by Meenakshi Prabhune, PhD, Editor-in-Chief at The Scientist, panellists delved into the advancements, challenges, and future directions of synthetic biology for human health. A huge shoutout to all the panellists: our CEO Mark Kotter, Kaan Certel from Sanofi, Jason Kelly from Ginkgo, Lesley Stolz from Johnson & Johnson and Professor Ron Weiss from MIT for their invaluable insights and expertise! Now, as we eagerly anticipate SynBioBeta 2024, we're thrilled to highlight part of this year's Main Stage content: "Gene Meets Cell: The SynBio Evolution in Targeted Therapeutics." 🧬 Join us for an electrifying session where we'll explore the cutting-edge realms of programmable gene and cell therapies, two of the most promising frontiers in synthetic biology. Featuring a stellar lineup of speakers including Avencia Sanchez-Mejias PhD from Integra Therapeutics, Anil Narasimha from Mekonos, Daniel Georgiev from Sampling Human and our very own Mark Kotter MD, PhD, Founder and CEO of bit.bio. Save the date: Thursday, 9th at 4:45 PM - 5:15 PM (Pacific time). Don't miss out on this unparalleled opportunity to delve into the future of medicine driven by synthetic biology! See you in San Jose! 🚀 https://hubs.ly/Q02tFPPC0 Watch Main Stage SynBioBeta 2023: https://hubs.ly/Q02tFC5z0 #SynBioBeta #SyntheticBiology #Biopharma #Medicine #GeneTherapy #CellTherapy John Cumbers

A team of researchers from Karolinska Institutet and SciLifeLab, led by Magda Bienko and Nicola Crosetto, have developed a new method capable of profiling extrachromosomal circular DNAs (eccDNAs) at single-cell resolution. The results shed light on how these circular DNA elements are generated and how they can influence tumorigenesis. The study is published in Nature Communications. Read more from Magda and Nicola, as well as Jinxin Phaedo Chen (PhD student in the Bienko-Crosetto Lab) in the article below ↓

Researchers in the lab of Nobel Prize winner Jennifer Doudna, PhD have designed enveloped delivery vehicles (EDVs) that can carry Cas9 and gRNA proteins for precise genome editing in living organisms. The engineered EDVs utilize the lentivirus’s ability to package molecules and transduce cells and antibodies’ ability to recognize cells on the surface. The EDVs were also used to send Cas9 protein, sgRNAs, and transgenes to specific cells in a culture of human cells. Read more with GenEng News! https://lnkd.in/dxVZMiwz #genomeengineering #CRISPR #CRISPRnews

Thrilled to finally share this work! Maite Huarte and I delve into the interplay between RNA regulation and DNA damage finding that "YTHDC1 m6A-dependent and m6A-independent functions converge to preserve DNA damage response"! Kudos to Daniel Elvira-Blázquez and the whole team for their outstanding contributions to advancing our understanding of molecular mechanisms in DNA damage response!🌟🔬🧬 https://lnkd.in/e7dduxRu

Salk Institute for Biological Studies is in the thick of its "Year of #HealthyAging," a campaign to understand the difference between aging in sickness or in health. Our latest study is a great example of how this gets done. You may have heard that telomeres—the protective endcaps on our chromosomes—get shorter as we age. They eventually get so whittled down that our chromosomes become exposed, and our cells die. But the specifics of when and how this happens, and whether certain chromosomes are more affected than others, have been unclear...until now. Salk scientists have teamed up with Oxford Nanopore Technologies to develop Telo-seq: a new tool that can determine the precise length and entire sequence of telomeres on individual human chromosomes. They're already seeing new telomere dynamics that were totally unobservable to scientists before this. Telo-seq will continue to teach us how telomeres contribute to aging, and will one day inspire new telomere-targeting therapeutics for aging-related diseases. You can read my latest press release to learn more. #SalkHealthyAging #Aging #Health #Biology #Biotech #DNA #Sequencing #Science #ScienceCommunication #SciComm https://lnkd.in/gBVjgMjB

Explore new dimensions of biology with single-cell nanopore sequencing Single-cell transcriptome sequencing is a powerful tool for profiling transcriptomic heterogeneity in health and disease. However, in the past it has relied on short-read sequencing technologies, which provide little information at the transcript level due to the inherent limitations in linking distal splicing events within the same transcript. With the advent of long-read capable sequencing technologies, such as that provided by Oxford Nanopore Technologies, we are ushering in a new era of single-cell sequencing, where transcripts can be viewed at the isoform level. https://lnkd.in/gpUvaGe4 #cDNAsequencing #isoforms #splicejunctions

Exciting news! Our next-gen multiomic immune profiling assays are here! Gain deeper insights about the immune repertoire in human and mouse samples with BD Rhapsody™ TCR/BCR Next Multiomic Assays. Probe full-length TCR/BCR sequences alongside RNA and protein information at the single-cell level to unravel immune biology. High pairing, the ability to work with preserved single-cell samples and reliable performance are just some of the key features of our new assay. Learn more at https://bit.ly/3y2SGNO If you’re at #AAI2024, stop by BD booth #732 to learn more about these assays. #TCRBCRNext #immuneprofiling #singlecellmultiomics #BDRhapsody #BDBiosciences

🧬 Today we focus on #BattenDisease (also known as neuronal ceroid lipofuscinosis, #NCL) a group of rare inherited nervous system disorders that typically begin in childhood and that are fatal. They interfere with a cell's ability to recycle a cellular residue called lipofuscin. 👧🏼 Over time, affected children experience mental impairment, worsening seizures and progressive loss of sight, speech and motor skills. With just one treatment available for a specific form of Batten, this group of disease has a strong medical need. 🔬 Thanks to a cell-based high content imaging (HCI) screening assay, Diego Luis Medina’s group at TIGEM tested a library of FDA-approved compounds and they found that tamoxifen improved the phenotype of Batten animal models. Medina’s group also showed that #Tamoxifen exerts its action through a mechanism that induced the activation of the transcription factor EB (TFEB), a master gene of lysosomal function and autophagy. 🎉 These preclinical results allowed Fondazione Telethon to obtain an #ODD (Orphan Drug Designation) for Tamoxifen in these conditions, a step closer to the clinical development and a therapeutic opportunity for Batten children. 🔗 More about Diego’s study here: https://lnkd.in/dMZH8TF8